InMed Pharmaceuticals (INM) Current Assets (2020 - 2026)

InMed Pharmaceuticals has reported Current Assets for 7 years, with the latest figure at $6.9 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 7.46% year-over-year to $6.9 million; the trailing twelve-month figure through Mar 2026 stood at $6.9 million (up 7.46% YoY), and the FY2025 full-year result was $12.9 million, up 48.08% from the prior year.
• Current Assets for Q1 2026 stood at $6.9 million, down from $8.8 million in the prior quarter.
• The five-year high for Current Assets was $14.0 million in Q4 2022, with the low at $5.5 million in Q4 2024.
• Historically, Current Assets has averaged $9.7 million across 5 years, with a median of $9.6 million in 2022.
• Annual changes were most pronounced in 2024 — Current Assets slumped 53.68% — and 2025, when it surged 60.67%.
• InMed Pharmaceuticals' Current Assets stood at $14.0 million in 2022, then slipped by 15.75% to $11.8 million in 2023, then tumbled by 53.68% to $5.5 million in 2024, then surged by 60.67% to $8.8 million in 2025, then decreased by 21.63% to $6.9 million in 2026.
• The last three Current Assets figures came in at $6.9 million (Q1 2026), $8.8 million (Q4 2025), and $10.8 million (Q3 2025), per Business Quant data.